Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder
Completed · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Healthy Volunteers (Part 1), Major Depressive Disorder (Part 2)
In brief
This is a two part study. The objective of Part 1 is to evaluate the safety, tolerability, and pharmacokinetics of HT-2157 in healthy normal volunteers Part 2 is a randomized, double-blind, placebo-controlled, multiple (21-day) ascending-dose evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of HT-2157 in patients with major depressive disorder
Key facts
- Study ID
- NCT01413932
- Run by
- Dart NeuroScience, LLC
- People needed
- 26
- Starts
- 2011-07-01
- Expected to finish
- 2012-12-01
- Last updated by the study team
- 2015-12-16
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clinical Site — Glendale, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.